Equillium Inc.

6.41-0.1700-2.58%Vol 90.53K1Y Perf 150.84%
Apr 13th, 2021 14:30 DELAYED
BID6.40 ASK6.46
Open6.68 Previous Close6.58
Pre-Market- After-Market-
 - -%  - -
Target Price
16.00 
Analyst Rating
Strong Buy 1.00
Potential %
149.61 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap186.15M 
Earnings Rating
Sell
Price Range Ratio 52W %
16.37 
Earnings Date
12th May 2021

Today's Price Range

6.336.68

52W Range

2.3727.05

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.08%
1 Month
-16.81%
3 Months
18.35%
6 Months
6.99%
1 Year
150.84%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EQ6.41-0.1700-2.58
AAPL134.413.17002.42
GOOG2 264.449.65000.43
MSFT258.062.15000.84
XOM55.690.19000.34
WFC39.80-0.9700-2.38
JNJ159.06-2.5800-1.60
FB312.330.79000.25
GE13.50-0.0900-0.66
JPM154.40-1.5500-0.99
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.38-0.365.26
Q03 2020-0.41-0.3124.39
Q02 2020-0.44-0.3715.91
Q01 2020-0.42-0.45-7.14
Q04 2019-0.40-0.44-10.00
Q03 2019-0.36-0.352.78
Q02 2019-0.34-0.35-2.94
Q01 2019-0.27-0.34-25.93
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.33-6.45Negative
6/2021 QR-0.34-9.68Negative
12/2021 FY-1.400.71Positive
12/2022 FY-1.669.78Positive
Next Report Date12th May 2021
Estimated EPS Next Report-0.33
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume90.53K
Shares Outstanding29.04M
Trades Count1.03K
Dollar Volume2.11M
Avg. Volume449.88K
Avg. Weekly Volume116.07K
Avg. Monthly Volume194.79K
Avg. Quarterly Volume443.46K

Equillium Inc. (NASDAQ: EQ) stock closed at 6.58 per share at the end of the most recent trading day (a -5.87% change compared to the prior day closing price) with a volume of 158.32K shares and market capitalization of 186.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Equillium Inc. CEO is Bruce D. Steel.

The one-year performance of Equillium Inc. stock is 150.84%, while year-to-date (YTD) performance is 22.99%. EQ stock has a five-year performance of %. Its 52-week range is between 2.37 and 27.05, which gives EQ stock a 52-week price range ratio of 16.37%

Equillium Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.87%, a ROC of -38.10% and a ROE of -51.66%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Equillium Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Equillium Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Equillium Inc. is Strong Buy (1), with a target price of $16, which is +149.61% compared to the current price. The earnings rating for Equillium Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Equillium Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Equillium Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.40, ATR14 : 0.85, CCI20 : -87.23, Chaikin Money Flow : -0.19, MACD : -0.14, Money Flow Index : 34.37, ROC : -4.50, RSI : 48.82, STOCH (14,3) : 19.21, STOCH RSI : 0.61, UO : 36.60, Williams %R : -80.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Equillium Inc. in the last 12-months were: Jason A. Keyes (Sold 8 000 shares of value $37 914 ), Stephen Connelly (Sold 275 000 shares of value $2 173 870 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Equillium Inc.

Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.

CEO: Bruce D. Steel

Telephone: +1 858 412-5302

Address: 2223 Avenida De La Playa, La Jolla 92037, CA, US

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

42%58%

Bearish Bullish

47%53%

Bearish Bullish

52%48%

News

Stocktwits